62/100BNatera financials
Not at the moment. Natera lost 164.71M USD over the last twelve months. It made a profit in 0 of its 14 fiscal years since 2012. Its last loss was in fiscal year 2025.
- Revenue (TTM)
- 2.91B USD
- Net income (TTM)
- -164.71M USD
- Free cash flow (TTM)
- 52.47M USD
- Cash and short-term investments
- 1.10B USD
- Total debt
- 222.91M USD
- Shareholders' equity
- 1.87B USD
Cash, debt and equity as of 30 Sept 2026.
Natera earnings
Revenue
EPS
| Period | Report date | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|---|
| Q2 FY2028 | 0.18 | — | — | — | 1.02B | — | — | — | |
| Q1 FY2028 | 0.16 | — | — | — | 958.06M | — | — | +17.74% | |
| Q1 FY2027 | -0.25 | — | — | — | 813.69M | — | — | +16.80% | |
| Q4 FY2026 | -0.11 | — | — | -130.03% | 749.53M | — | — | +12.63% | |
| Q3 FY2026 | -0.28 | -0.42 | -49.34% | — | 707.54M | 793.98M | +12.22% | +34.08% | |
| Q2 FY2026 | -0.49 | -0.47 | +4.85% | — | 661.24M | 752.75M | +13.84% | +37.71% | |
| Q1 FY2026 | -0.54 | -0.56 | -3.28% | — | 617.10M | 696.64M | +12.89% | +38.82% | |
| Q4 FY2025 | -0.51 | 0.35 | +168.35% | — | 604.04M | 665.50M | +10.18% | +39.79% | |
| Q3 FY2025 | -0.39 | -0.64 | -65.94% | — | 513.45M | 592.18M | +15.33% | +34.66% | |
| Q2 FY2025 | -0.62 | -0.74 | -20.24% | — | 476.26M | 546.60M | +14.77% | +32.24% |
| Period | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|
| FY2028 | 1.27 | — | — | — | 4.26B | — | — | +21.13% |
| FY2027 | -0.37 | — | — | — | 3.52B | — | — | +20.89% |
| FY2026 | -1.45 | — | — | — | 2.91B | — | — | +26.20% |
| FY2025 | -2.40 | -1.53 | +36.18% | — | 2.24B | 2.31B | +2.83% | +35.90% |
| FY2024 | -1.50 | -1.53 | -2.17% | — | 1.65B | 1.70B | +2.73% | +56.75% |
| FY2023 | -3.96 | -3.79 | +4.27% | — | 1.07B | 1.08B | +1.17% | +31.99% |
| FY2022 | -5.60 | -5.57 | +0.58% | — | 819.43M | 820.22M | +0.10% | +31.13% |
Natera growth and profitability
Full income statement- Revenue (TTM)
- 2.91B USD
- Net income (TTM)
- -164.71M USD
- Gross margin
- 65.24%
- Operating margin
- -8.95%
- Net margin
- -5.66%
Revenue / Net income
Natera revenue breakdown
By product
| Segment | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| Product | 2.30B | 99.6% | +36.2% |
| Licensing and other | 10.29M | 0.4% | -13.0% |
By region
| Region | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| United States | 2.26B | 98.2% | +36.6% |
| Europe, Middle East, India, and Africa | 24.48M | 1.1% | — |
| Americas, excluding U.S. | 9.35M | 0.4% | +41.3% |
| Asia Pacific and Other | 8.01M | 0.3% | -7.5% |
Operating and free cash flow
Full cash flow statementNatera financial health
Full balance sheet- Cash and short-term investments
- 1.10B USD
- Total debt
- 222.91M USD
- Net cash
- 874.28M USD
- Free cash flow (TTM)
- 52.47M USD
- Current ratio
- 2.81
- Debt to equity
- 0.12
- Piotroski score
- 2 / 9
- Altman Z-score
- 35.55
Cash, debt and free cash flow
Assets, liabilities and equity
Natera valuation
- Forward P/E (FY2028)
- 243.41
- Price to sales (TTM)
- 15.38
- Price to book
- 23.92
Capital structure
Valuation over time
Natera against its own history
Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.
Its peers: IDEXX Laboratories, Agilent Technologies, Waters, IQVIA Holdings, Mettler-Toledo International, and Illumina, the US Medical - Diagnostics & Research companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.
- Gross marginHighest in 5 years64.8%44.4%64.8%Against its peers: 2 of 7Peers' median 58.6%
- Operating marginAbove its median-13.4%-74.8%-13.1%Against its peers: 7 of 7Peers' median 24.5%
- Net marginHighest in 5 years-9.0%-75.4%-9.0%Against its peers: 7 of 7Peers' median 19.9%
- Return on equityHighest in 5 years-12.2%-77.6%-12.2%Against its peers: 6 of 6Peers' median 25.1%
- Free cash flow marginHighest in 5 years4.7%-60.2%4.7%Against its peers: 7 of 7Peers' median 19.1%
- Revenue growthAt its median35.9%31.1%60.0%Against its peers: 1 of 7Peers' median 6.3%
- Current ratioLowest in 5 years3.393.394.99Against its peers: 1 of 7Peers' median 1.45
Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.
Natera ownership
- Institutions
- 96.26%
- Institutional holders
- 886 (+94)
- Free float
- 93.58%
Who owns the shares
Shares free to trade
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Insider trading
| Quarter | Purchases | Sales | Shares acquired | Shares disposed of |
|---|---|---|---|---|
| Q4 2026 | 0 | 85 | 50.00K | 143.10K |
| Q3 2026 | 0 | 139 | 20.00K | 276.86K |
| Q2 2026 | 0 | 124 | 87.40K | 364.12K |
| Q1 2026 | 0 | 116 | 701.15K | 865.71K |
Shares outstanding
Common questions about Natera's financials
Source: Financial Modeling Prep